<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Sex-specific Mendelian randomization estimates (where possible) for effects of genetically mimicked statins, PCSK9 inhibitor and ezetimibe (in effect sizes of LDL-cholesterol) on testosterone (effect size) in men and women using the UK Biobank .</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top"/><th valign="top"/><th valign="top"/><th colspan="4" valign="top">Mendelian Randomization estimates</th></tr><tr><th valign="top"/><th valign="top">Therapy</th><th valign="top"># SNPs</th><th valign="top">Method</th><th valign="top">Beta</th><th valign="top">95% CI</th><th valign="top">P value</th><th valign="top">MR-Egger intercept p-value</th></tr></thead><tbody><tr><td valign="top">Men</td><td valign="top">Statin</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">&#8722;0.15</td><td valign="top">&#8722;0.23 to &#8722;0.06</td><td valign="top">0.001</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">&#8722;0.15</td><td valign="top">&#8722;0.23 to &#8722;0.07</td><td valign="top">0.0005</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">&#8722;0.11 to 0.18</td><td valign="top">0.63</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.07</td><td valign="top">&#8722;0.13 to 0.27</td><td valign="top">0.29</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.34</td><td valign="top">0.09 to 0.60</td><td valign="top">0.01</td><td valign="top">&#8722;0.01 (0.01)</td></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">7</td><td valign="top">Inverse variance weighted</td><td valign="top">0.05</td><td valign="top">&#8722;0.05 to 0.15</td><td valign="top">0.29</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">&#8722;0.15 to 0.23</td><td valign="top">0.68</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.05</td><td valign="top">&#8722;0.12 to 0.22</td><td valign="top">0.55</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.03</td><td valign="top">&#8722;0.13 to 0.18</td><td valign="top">0.72</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.24</td><td valign="top">&#8722;0.52 to 1.0</td><td valign="top">0.54</td><td valign="top">&#8722;0.01 (0.52)</td></tr><tr><td valign="top">Women</td><td valign="top">Statin</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">&#8722;0.06 to 0.14</td><td valign="top">0.45</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">0.03</td><td valign="top">&#8722;0.07 to 0.13</td><td valign="top">0.52</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.01</td><td valign="top">&#8722;0.11 to 0.14</td><td valign="top">0.85</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.01</td><td valign="top">&#8722;0.13 to 0.15</td><td valign="top">0.91</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.09</td><td valign="top">&#8722;0.38 to 0.56</td><td valign="top">0.71</td><td valign="top">&#8722;0.003 (0.74)</td></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">7</td><td valign="top">Inverse variance weighted</td><td valign="top">&#8722;0.004</td><td valign="top">&#8722;0.14 to 0.13</td><td valign="top">0.95</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.18</td><td valign="top">&#8722;0.05 to 0.40</td><td valign="top">0.12</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.12</td><td valign="top">&#8722;0.08 to 0.31</td><td valign="top">0.24</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account their correlations.</p><p>Three PCSK9 inhibitor SNPs are rs11206510, rs2149041 and rs7552841, and 7 PCSK9 inhibitor SNPs additionally included rs10888897, rs2479394, rs2479409 and, rs562556 taking into account all their correlations.</p></fn><fn><p>One ezetimibe SNP is rs2073547 (proxied by rs10260606), and three ezetimibe SNPs additionally included rs7791240 and rs217386 taking into account all their correlations.</p><p>The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women (<xref ref-type="bibr" rid="bib24">Haring et al., 2012</xref>) and 3.1 nmol/L in men (<xref ref-type="bibr" rid="bib39">Mohr et al., 2005</xref>).</p></fn></table-wrap-foot></table-wrap>